Sotatercept for the Treatment of Pulmonary Arterial Hypertension | Zendy

Marc Humbert | Zendy; Vallerie V. McLaughlin | Zendy; J. Simon R. Gibbs | Zendy; Mardi GombergMaitland | Zendy; Marius M. Hoeper | Zendy; Ioana R. Preston | Zendy; Rogério Souza | Zendy; Aaron B. Waxman | Zendy; Pilar Escribano Subías | Zendy; Jeremy Feldman | Zendy; G. Meyer | Zendy; David Montani | Zendy; Karen M. Olsson | Zendy; Solaiappan Manimaran | Zendy; Jennifer Barnes | Zendy; Peter G. Linde | Zendy; Janethe de Oliveira Pena | Zendy; David B. Badesch | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Sotatercept for the Treatment of Pulmonary Arterial Hypertension

Author(s) -

Marc Humbert,

Vallerie V. McLaughlin,

J. Simon R. Gibbs,

Mardi GombergMaitland,

Marius M. Hoeper,

Ioana R. Preston,

Rogério Souza,

Aaron B. Waxman,

Pilar Escribano Subías,

Jeremy Feldman,

G. Meyer,

David Montani,

Karen M. Olsson,

Solaiappan Manimaran,

Jennifer Barnes,

Peter G. Linde,

Janethe de Oliveira Pena,

David B. Badesch

Publication year - 2021

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2024277

Subject(s) - cardiology , medicine , pulmonary hypertension

Pulmonary arterial hypertension is characterized by pulmonary vascular remodeling, cellular proliferation, and poor long-term outcomes. Dysfunctional bone morphogenetic protein pathway signaling is associated with both hereditary and idiopathic subtypes. Sotatercept, a novel fusion protein, binds activins and growth differentiation factors in the attempt to restore balance between growth-promoting and growth-inhibiting signaling pathways.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research